USFDA7 Feb 2026, 12:51 pm
Ipca Laboratories' Tarapur Facility Receives US FDA Inspection Report with 'Voluntary Action Indicated' Status
AI Summary
Ipca Laboratories Ltd has informed BSE about a US FDA inspection of their Active Pharmaceutical Ingredients (API) manufacturing facility at Tarapur, Palghar-Maharashtra. The inspection took place from 1st to 5th December, 2025. The facility has now received an Establishment Inspection Report, classifying it as 'Voluntary Action Indicated (VAI)'. This indicates that the facility is in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).
Key Highlights
- Ipca Laboratories' Tarapur facility underwent a US FDA inspection from 1st to 5th December, 2025
- The facility received an Establishment Inspection Report from the US FDA
- The report classifies the facility as 'Voluntary Action Indicated (VAI)'
- This classification indicates a minimally acceptable state of compliance with CGMP
- The inspection and report pertain to the Tarapur facility's API manufacturing